HWM
KRYS icon

Hohimer Wealth Management’s Krystal Biotech KRYS Stock Holding History

Hohimer Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Sell
1,034
-180
-15% -$47.9K 0.03% 249
2025
Q4 		$299K Sell
1,214
-1
-0.1% -$210 0.04% 224
2025
Q3 		$214K Buy
+1,215
New +$182K 0.03% 297

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hohimer Wealth Management's KRYS Position: Q1 2026 in Review

Hohimer Wealth Management reduced its Krystal Biotech (KRYS) stake by 15% in Q1 2026, selling an estimated $47.9K and leaving 1,034 shares worth $267K. The position accounts for 0.03% of the portfolio, ranked #249.

Hohimer Wealth Management first reported a position in KRYS in Q3 2025 and has held it in 3 quarters since. The position peaked at $299K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Hohimer Wealth Management held 1,034 shares of Krystal Biotech worth $267K as of Q1 2026.
  • Hohimer Wealth Management sold 180 Krystal Biotech shares in Q1 2026, an estimated $47.9K.
  • Krystal Biotech made up 0.03% of Hohimer Wealth Management's portfolio in Q1 2026, its #249 holding.
  • Hohimer Wealth Management first reported a position in Krystal Biotech in Q3 2025 and has held it in 3 quarters since.
  • Hohimer Wealth Management's Krystal Biotech position peaked at $299K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Hohimer Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.